Volumetric MRI-guided, high-intensity focused ultrasound ablation of uterine leiomyomas: ASEAN preliminary experience.
CONCLUSION: The preliminary results demonstrated that volumetric MRI-guided HIFU therapy for the treatment of symptomatic leiomyomas in ASEAN patients appears to be clinically acceptable with regard to treatment effectiveness and safety. PMID: 32209511 [PubMed - as supplied by publisher]
Authors: Sanders AP, Shirreff L PMID: 32473978 [PubMed - as supplied by publisher]
Calster B, Timmerman D Abstract OBJECTIVE: To describe the ultrasound features of different endometrial and other intracavitary pathologies in pre- and postmenopausal women presenting with abnormal uterine bleeding using the International Endometrial Tumor Analysis (IETA) terminology. METHODS: Prospective observational multicenter study of 2856 consecutive women presenting with abnormal uterine bleeding. Unenhanced ultrasonography with color Doppler was performed in all cases and fluid instillation sonography in 1857. Endometrial sampling was performed according to each center's local protocol. In 2216 ...
The lesions in esophagogastric junction (EGJ) are difficult for treatment. The operative resection of the gastric cardia causes the diminishment of quality of life. The endoscopic treatment has been developed for the resection of submucosal tumors (SMTs). The techniques of endoscopic resection for the SMTs originating from the muscularis propria (MP) layer mainly include endoscopic submucosal dissection (ESD) and submucosal tunneling endoscopic resection (STER). The safety and efficacy of ESD and STER for EGJ SMTs has been demonstrated.
Gastrointestinal submucosal tumor (SMT) shown as a hypoechoic mass lesion in endoscopic ultrasonography (EUS) mainly includes gastrointestinal stromal tumor (GIST), leiomyoma and schwannoma, and it is difficult to distinguish them by using imaging modalities. Although EUS-guided fine-needle aspiration is a standard option to diagnose SMTs, that is more or less invasive and sometimes less satisfactory due to insufficient amount of obtained tissue. Therefore, a new non-invasive and more reliable diagnostic method is still desired.
Uterine fibroids (UF; leiomyomas) are common, benign, gynecological smooth-muscle tumors occurring in up to 80 % of women by 50 years of age [1 –4]. Symptoms include heavy menstrual bleeding (HMB), anemia, moderate/severe pain, pressure, infertility, and pregnancy complications [3–5], which have a considerable effect on women’s quality of life (QoL), causing psychological distress and placing substantial financial burden on patients a nd healthcare systems [1,6–8].
Uterine fibroids (leiomyoma) are benign monoclonal neoplasms of the myometrium and represent the most common tumors in women worldwide. Tumors occur in ∼77% of women overall and are clinically manifest in ∼25% by age 45 years. Although benign, these tumors are nonetheless associated with significant morbidity; they are the primary indication for hysterectomy, and a major source of gynecologic and reproductive dysfunction, ranging from profuse m enstrual bleeding and pelvic pain to infertility, recurrent miscarriage, and preterm labor.
Publication date: Available online 29 May 2020Source: International Journal of Surgery Case ReportsAuthor(s): Kaoru Wada, Hirofumi Tazawa, Toshiaki Komo, Naoto Hadano, Takashi Onoe, Takeshi Sudo, Yosuke Shimizu, Kazuya Kuraoka, Takahisa Suzuki, Hirotaka Tashiro
ConclusionsWe must keep in mind that ESCC or high-grade dysplasia can occur overlying leiomyoma. These cases are rare but should not be neglected, especially in high-risk areas for ESCC. These patients can receive appropriate treatment if overdiagnosis or underdiagnosis can be avoided.
Conclusion: This rare case demonstrates the importance of MR imaging to differentiate intra-neural leiomyomas from other benign peripheral nerve sheath tumors. Surgical treatment plays an important role in the treatment of patient with intraneural leiomyoma with neurologic deficits.
CONCLUSION: Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss in women with uterine leiomyomas, with the addition of add-back therapy attenuating the hypoestrogenic effects of elagolix alone. No new or unexpected safety concerns were associated with an additional 6 months of elagolix with addback therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02925494. FUNDING SOURCE: AbbVie Inc funded this study. PMID: 32459423 [PubMed - in process]